What is AHK-Cu?

AHK-Cu is the copper complex of the tripeptide alanine-histidine-lysine. It sits in the same broad copper-peptide family as GHK-Cu, but the first amino acid differs: AHK begins with alanine, while GHK begins with glycine. [1][2][3]

The direct AHK-Cu literature is much narrower than the GHK-Cu literature. Its anchor study used isolated human hair follicles and cultured dermal papilla cells, which makes it useful for hair-follicle biology but not enough to claim proven hair regrowth in people. [1][5]

The biological reason people care is straightforward: dermal papilla cells help control the hair-growth cycle, and AHK-Cu is linked with follicle elongation, dermal papilla cell proliferation, and anti-apoptotic markers. In plain terms, it points to a follicle-support signal under laboratory conditions. [1]

AHK-Cu should not be collapsed with GHK-Cu or Pal-AHK. GHK-Cu is the better-studied copper tripeptide for skin remodeling, while Pal-AHK is a palmitoylated derivative designed for topical delivery. Related structure does not make the evidence interchangeable. [1][2][4]

What AHK-Cu is investigated for

AHK-Cu evidence is grouped by practical use case and topical route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Hair follicle elongation

Topical

30% Limited

AHK-Cu has an ex vivo follicle-elongation signal, but proven topical hair regrowth in people has not been shown. [1]

Human evidence

No controlled human scalp outcome trial was identified for AHK-Cu. The available follicle-elongation evidence uses isolated human follicles outside the body, not topical use in people. [1][6]

Animal / mechanistic evidence

AHK-Cu stimulated elongation of human hair follicles ex vivo at laboratory concentrations. [1]

Dermal papilla cell proliferation

Topical

30% Limited

Dermal papilla cell proliferation is a plausible hair-growth mechanism, but clinical hair-loss efficacy has not been established. [1]

Human evidence

No finished-product human scalp trial was identified that shows AHK-Cu increases dermal papilla cell activity in vivo. [6][1]

Animal / mechanistic evidence

Cultured dermal papilla cells showed proliferation with AHK-Cu; this follicle-cell population is involved in hair-cycle signaling. [1]

Hair-follicle cell survival signaling

Topical

28% Limited

Hair-follicle cell-survival signaling is plausible follicle support, but anti-shedding or hair-restoration outcomes remain unproven. [1]

Human evidence

No controlled human outcome source shows that AHK-Cu reduces follicle-cell apoptosis on the scalp. [6]

Animal / mechanistic evidence

AHK-Cu shifted anti-apoptotic markers in dermal papilla cells, including a higher Bcl-2/Bax ratio and lower cleaved caspase-3 and PARP measures. [1]

VEGF and TGF-beta skin signaling

Topical

28% Limited

VEGF and TGF-beta changes are laboratory signals for skin and follicle biology; human skin-repair or anti-aging outcomes are not established. [1]

Human evidence

No controlled human topical AHK-Cu clinical trial was identified for skin vascular signaling, wrinkle appearance, or wound outcomes. [6]

Animal / mechanistic evidence

Dermal fibroblast laboratory models showed proliferation, elevated VEGF production, and reduced TGF-beta1 secretion with AHK-Cu. [1]

Collagen type I support

Topical

26% Limited

Collagen type I support has AHK-Cu laboratory evidence, but topical collagen remodeling in people has not been established. [1][2]

Human evidence

No controlled human AHK-Cu topical skin-aging or collagen-density outcome trial was identified. [6][2]

Animal / mechanistic evidence

Dermal fibroblast laboratory models showed increased collagen type I production with AHK-Cu. [1]

Evidence snapshot

Overall confidence

Limited

42%

The AHK-Cu evidence base is narrow but concrete: one direct human-follicle laboratory paper plus broader copper-peptide and cosmetic-peptide literature. Human scalp outcomes remain unproven. [1][5][4]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

12%

Human evidence

Insufficient

No controlled human scalp outcome trial was identified for AHK-Cu under the reviewed ingredient names. [1][6]

36%

Animal / preclinical

Limited

Preclinical support is concentrated in one ex vivo and cell-culture human-follicle paper. It reported follicle elongation, dermal papilla proliferation, anti-apoptotic markers, VEGF and TGF-beta changes, and collagen type I production, but no finished-product scalp outcomes. [1]

38%

Mechanism support

Limited

The lab signal includes follicle elongation, dermal papilla cell proliferation, and anti-apoptotic markers, which supports plausibility without proving clinical regrowth. [1]

Forms & administration

AHK-Cu fits best as a topical/scalp cosmetic ingredient. Injection, mesotherapy, and drug-treatment claims should not be inferred from the current AHK-Cu evidence base. [1][4][7]

Topical

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Use the finished product label. Laboratory follicle and dermal papilla concentrations do not define a consumer scalp dose range. [1][4]

Frequency

Topical scalp routines usually work best when the same product schedule is followed consistently enough to compare photos and shedding notes. [5][4]

Timing Considerations

Morning or evening timing can be chosen around hair washing, styling, and irritation tolerance. Avoid starting several new scalp actives on the same day. [4]

Cycle Length

Use weeks-to-months photo tracking for scalp cosmetic routines because hair-cycle changes are slow and day-to-day shedding is noisy. [5][1]

Protocol Notes

Do not treat AHK-Cu as a substitute for evidence-based hair-loss drugs. If minoxidil, finasteride, dutasteride, procedures, or prescription scalp medicines are in use, track AHK-Cu separately. [1][8]

What to expect

First 1-2 weeks

Scalp feel: calmer-feeling scalp, easy absorption, manageable residue, and a routine that fits daily use. [4][5]

Weeks 8-12

Subtle hair-cosmetic changes: steadier shedding patterns, slightly better hair feel, or a fuller-looking part line in consistent photos. [1][5]

Months 3-6

Gradual hair-cycle changes: reduced visible scalp, improved hair caliber, or more stable shedding patterns alongside the rest of the routine. [5][1]

After stopping

Scalp feel, shedding pattern, or visible density may gradually drift back toward baseline as the topical routine drops out, with hair-cycle changes moving slowly rather than day to day. [5][1]

Safety profile

AHK-Cu safety is best handled as topical cosmetic safety plus evidence gaps. Monitor scalp irritation and product tolerability; do not infer injectable or disease-treatment safety from the current literature. [4][7][1]

Common side effects

Scalp redness [4]
Itching or burning [4]

Cautions

Open or inflamed scalp [7]
Injectable use [8][7]

What we don't know

Human scalp efficacy, topical pharmacokinetics, ideal concentration, long-term scalp safety, pregnancy safety, and interaction data remain unresolved. [1][6]

Who AHK-Cu is not for

Route-specific avoid and medical-review notes:

Active scalp disease or open skin
Use medical review first for infection, open lesions, severe dermatitis, psoriasis flares, unexplained hair loss, or sudden shedding. [7][5]
Pregnancy, breastfeeding, or pediatric use
Dedicated AHK-Cu safety data are not established for pregnancy, breastfeeding, or pediatric cosmetic use. [4]
Known cosmetic ingredient sensitivity
People with previous reactions to peptide, copper-complex, preservative, fragrance, or solvent systems should treat new AHK-Cu products cautiously. [4]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Other irritating scalp actives
Layering AHK-Cu with minoxidil vehicles, retinoids, acids, dyes, harsh shampoos, or microneedling can make irritation harder to interpret. [4][5]
Additional copper peptides
Using several copper-peptide products at once can make irritation, staining, or tolerability attribution unclear; combination evidence is not established. [2][4]

Regulatory status

United States

United States: no FDA-approved AHK-Cu drug product was identified in the reviewed openFDA query. Topical cosmetic scalp products are regulated separately from drugs; hair-loss treatment claims can create drug claims. [8][7]

Route	FDA drug approval	503A compounding
Topical	Not Approved openFDA Drugs@FDA queries for AHK-Cu and Copper Tripeptide-3 returned no matching approved drug product. Cosmetic scalp products are separate from therapeutic hair-loss drug claims. [8][7]	Not Listed The current 503A bulk-substances PDF review did not identify AHK-Cu or Copper Tripeptide-3 as a listed nominated substance. That absence does not turn cosmetic availability into drug approval. [9]

Topical

FDA drug approval

Not Approved

openFDA Drugs@FDA queries for AHK-Cu and Copper Tripeptide-3 returned no matching approved drug product. Cosmetic scalp products are separate from therapeutic hair-loss drug claims. [8][7]

503A compounding

Not Listed

The current 503A bulk-substances PDF review did not identify AHK-Cu or Copper Tripeptide-3 as a listed nominated substance. That absence does not turn cosmetic availability into drug approval. [9]

International

International status is market-, product-, and claim-specific. EU/Europe, the UK, Canada, and Australia regulate cosmetic products through cosmetic or industrial-chemical frameworks, while therapeutic hair-loss claims may trigger medicine or drug rules. [10][11][12][13]

Sports & competition

Topical cosmetic AHK-Cu has no specific anti-doping issue identified in the reviewed materials. Systemic or injectable use is not athlete-cleared, and non-approved-substance logic can matter when a product is used as an unapproved drug. [14][8]

How it works

The dermal papilla is a signaling hub at the base of the hair follicle. AHK-Cu is mechanistically interesting because its lab signal involves this follicle compartment rather than only generic skin fibroblasts. [1]

Follicle elongation and dermal papilla cell activity make AHK-Cu mechanistically plausible for scalp support. That is a lower-confidence statement than saying it treats hair loss. [1]

The copper-peptide family relationship helps explain why AHK-Cu gets compared with GHK-Cu, but GHK-Cu's skin-remodeling evidence should not be copied into AHK-Cu hair claims. [1][2]

Research gaps & open questions

What the current literature has not yet settled about AHK-Cu:

Controlled human scalp outcome trials are needed before AHK-Cu can be ranked as a supported hair-loss intervention. [1][6]

Finished-product formulation studies should define whether topical AHK-Cu reaches follicle-relevant targets at useful concentrations. [4][1]

Head-to-head or add-on studies are needed to know whether AHK-Cu adds meaningful benefit next to established hair-loss therapies. [5][1]

AHK-Cu, GHK-Cu, and Pal-AHK need separate route and formulation comparisons instead of family-level evidence transfer. [1][2][4]

Common questions

Is AHK-Cu the same as GHK-Cu?

No. Both are copper tripeptides, but AHK-Cu has alanine in the first position and a much narrower hair-follicle evidence base, while GHK-Cu has broader skin-remodeling literature. [1][2]

Is AHK-Cu clinically proven to regrow hair?

No. The direct evidence is an ex vivo and in vitro human hair-follicle study, not a controlled human scalp trial. [1][6]

Is AHK-Cu topical or injectable?

AHK-Cu is best treated as a topical/scalp cosmetic ingredient. Injectable or mesotherapy use has no established clinical basis in the reviewed sources and should not be inferred from cosmetic products. [7][8]

Can AHK-Cu replace minoxidil or prescription hair-loss treatment?

No. AHK-Cu is a preclinical follicle-support ingredient, not an evidence-based replacement for established medical hair-loss therapies. [1][8]

Is AHK-Cu the same as Pal-AHK?

No. AHK-Cu is the copper complex, while Pal-AHK is a palmitoylated derivative discussed for cosmetic delivery. Their evidence should be reviewed separately. [1][4]

Myths & misconceptions

Myth

AHK-Cu is a clinically proven hair-loss treatment.

Reality

Isolated follicles and cultured dermal papilla cells show meaningful follicle biology, but they are not a controlled human hair-loss trial. [1]

Myth

AHK-Cu can use the same evidence score as GHK-Cu.

Reality

The family relationship is real, but GHK-Cu's skin-remodeling evidence does not prove AHK-Cu scalp outcomes. [1][2]

Myth

Injecting AHK-Cu into the scalp works better than topical use.

Reality

Injectable AHK-Cu is not supported by the reviewed evidence and cosmetic products are not sterile injectable medicines. [7][8]

History & discovery

AHK-Cu entered the hair-peptide conversation through a 2007 laboratory study using isolated human hair follicles and dermal papilla cells, then spread into cosmetic scalp-product and copper-peptide discussions. [1][5]

Pyo and colleagues reported that AHK-Cu stimulated elongation of isolated human hair follicles and proliferation of cultured dermal papilla cells. [1]

Cosmetic and hair anti-aging reviews discussed peptides, copper tripeptides, and topical hair-support ingredients, while emphasizing the broader problem of limited randomized clinical evidence for many cosmetic peptides. [4][5]